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Abstract
Chronic  HCV  co-infection  is  present  in  up  to  one
third  of  HIV-positive  patients  in  Europe.  In  recent
years, apart from the traditional transmission route of
intravenous drug abuse, outbreaks of sexually trans-
mitted acute HCV infections, mainly among HIV-posi-
tive men who have sex with men, have contributed to
the overall disease burden. 
Because  the  natural  course  of  HCV  infection  is
substantially  accelerated  in  HIV-co-infection,  end-
stage liver disease has become the most frequent cause
of non-aIDs related death in this population. There-
fore  every  HIV/HCV  co-infected  patient  should  be
evaluated for possible anti-HCV therapy with the goal
of reaching a sustained virological response and thus
cure of hepatitis C infection. The standard of care for
the treatment of chronic HCV infection in HIV-in-
fected remains a pegylated interferon in combination
with weight-adapted ribavirin. 
HaaRT should not be withheld from HCV co-in-
fected patients due to concerns of drug related hepa-
totoxicity  and  in  patients  with  reduced  CD4-cell
counts HaaRT should be started first. under pegylat-
ed interferon and ribavirin combination therapy drug
to drug interactions and cumulated toxicity between
nucleoside  analogues  and  anti-HCV  therapy  may  be
observed  and  concomitant  didanosine  use  is  con-
traindicated and zidovudine and stavudine should be
avoided if possible. 
The development of new drugs for the treatment
of  chronic  hepatitis  C  represents  a  promising  per-
spective also for HIV positive patients. However, these
substances  will  probably  reach  clinical  routine  for 
HIV patients later than HCV monoinfected patients.
Therefore at present waiting for new drugs is not an
alternative to a modern pegylated interferon/ribavirin 
therapy. 
InTRoDuCTIon
With  the  availability  of  highly  active  antiretroviral
therapy (HaaRT) in 1996 [1], a dramatic decline of
aIDs-associated  mortality  has  been  observed.  ac-
cordingly, in the health management of the aging HIV-
positive patient, co-morbidities such as chronic liver
and cardiovascular disease are increasingly demanding
clinical attention. In hepatitis C virus (HCV) co-infect-
ed patients liver-related disease has emerged as a lead-
ing  cause  of  morbidity  and  mortality  [2].  owing  to
similar routes of transmission, HCV and HIV are of-
ten found in the same host. In Europe, up to one third
of all HIV patients are co-infected with HCV [3]. 
The progression of chronic HCV infection to liver
cirrhosis with subsequent risk for liver decompensa-
tion and hepatocellular carcinoma is substantially ac-
celerated in HIV/HCV co-infected compared to HCV
mono-infected  individuals  [4,  5].  The  sequelae  of
chronic hepatitis C infection however may be stopped
by successful treatment with pegylated interferon and
ribavirin  combination  therapy  so  that  every
HIV/HCV coinfected patient should be evaluated for
possible HCV treatment [6]. 
In the following review we want to summarize the
current  epidemiological  and  treatment  data  and  dis-
cuss these with particular regard to the recently updat-
ed guidelines of the European aIDs society in 2009
for the treatment of chronic hepatitis C infection in
HIV coinfected patients.
EPIDEMIoloGy
little is known on the epidemiology of HCV infection
in the setting of HIV co-infection. Recently the Eu-
rosIDa  cohort,  the  largest  prospective  cohort  of
HIV-positive patients in Europe, was analyzed to this
regard [3]. Within EurosIDa, of 14 310 patients who
were tested at enrollment 3 375 (24%) were anti-HCV
positive at baseline. There are, however, marked differ-
ences in the prevalence of positive anti-HCV antibod-
ies  throughout  Europe,  reflecting  differences  in  the
proportion  of  HIV  infections  transmitted  via  intra-
venous drug abuse, still the most important risk factor
for  the  acquisition  of  hepatitis  C  in  the  European
HIV-positive population [7]. Whereas countries with a
traditionally high burden of HIV-positive intravenous
drug  abusers  have  high  rates  of  HCV  co-infection
with 47% and 41% of patients in Eastern and south-
ern Europe positive for anti-HCV antibodies, respec-
tively, countries with MsM being the prevailing mode
of  HIV-transmission  have  lower  rates  of  chronic
HCV infection with a prevalence of anti-HCV anti-
body  of  20%  and  23%  of  patients  in  Central  and
northern  Europe,  respectively  [8].  These  rates  are
clearly higher compared to the HIV-negative popula-
tion,  where  rates  of  HCV-prevalence  have  been  re-
ported  to  be  between  2.5  –  10%  in  Romania  and
ukraine and 1 – 2.5 % in the remaining countries of
the WHo region of Europe [9]. With the implementa-
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tion and social prevention efforts a further expansion
of  intravenous  drug  abuse  related  HCV  infections
have been successfully contained in Western Europe.
for  instance,  in  spain  a  significant  decrease  in  the
overall prevalence of HCV co-infection among span-
ish patients newly diagnosed with HIV has been ob-
served, decreasing from 24% in 2000 - 2002 down to
10% in the period 2006 – 2008 [10]. unfortunately in
Eastern Europe, where harm reduction strategies have
not yet been installed on a large scale [11], the HIV
and HCV epidemic among intravenous drug abusers is
at risk to continue unbroken in some countries [12]. 
In Western Europe, and recently the usa and aus-
tralia, new outbreaks of sexually transmitted HCV in-
fections have been reported among men who have sex
with men [7, 13-22], which continue to increase the
disease burden of HCV co-infection within the HIV
community and worries have been raised that this epi-
demic may leap over and spread within the HIV-nega-
tive MsM community as a “new” sexually transmitted
disease. These concerns may be overstated as in a re-
cent  epidemiological  survey  among  genito-uterine
medicine  (GuM)  and  HIV  clinics  in  london  and
Brighton area on acute HCV infections among MsM,
of 395 acute HCV infections between 2002 and 2006,
389 had occurred in HIV-positive patients [15]. simi-
larly  urbanus  and  colleagues  investigated  into  the
prevalence of HCV infection among MsM attending
the sexually transmitted disease clinic in amsterdam
[20].  They  found  a  significantly  higher  HCV  preva-
lence  among  those  co-infected  with  HIV  (28 / 157,
18%) and history of intravenous drug use, fisting, and
the use of gamma hydroxy butyrate (GHB) were all
significantly associated with an increased risk for HCV
infection. only two of 532 HIV-negative MsM were
found to be HCV positive, and one of these reported
previous  intravenous  drug  and  these  observations
would be in line with past longitudinal studies of HCV
serodiscordant  heterosexual  partnerships,  where  the
life-time risk for sexual transmission of HCV was esti-
mated to be < 1% [23, 24]. nevertheless in the MsM
population due to different sexual practices the risk
for  sexually  acquired  HCV  infection  may  be  higher
than  among  heterosexual  couples  and  increases  of
acute HCV infections among HIV-negative MsM have
been reported. Continued prevention efforts on sexual
transmission of HCV within the MsM community, re-
gardless of HIV serostatus, therefore only appear pru-
dent [25]. 
naTuRal CouRsE of HEPaTITIs C 
In HIV Co-InfECTIon
While hepatitis C infection does not have a relevant
influence on the course of HIV infection, HIV infec-
tion accelerates the natural course of hepatitis C infec-
tion. HIV/HCV coinfected patients show a rapid pro-
gression of liver fibrosis in contrast to HCV monoin-
fected patients [4, 26]. of 174 HIV/HCV coinfected
patients which showed at the time-point of the first
liver biopsy no or only minimal fibrosis, one third pro-
gressed more than two fibrosis stages on a scale from
0-6 (IsHaK score) [5]. Indeed in the HaaRT era end-
stage liver-disease has become the main cause of mor-
bidity and mortality in HIV/HCV coinfected patients
[2].  Thus  it  is  crucial  for  the  future  health  of  each
HIV/HCV coinfected patient to assess risks and bene-
fits  of  a  pegylated  interferon  ribavirin  combination
therapy. a successful treatment of chronic hepatitis C
has not only proven to stop the progression of liver fi-
brosis but to result in a survival benefit for patients 
[6, 27].
PEGylaTED InTERfERon anD RIBaVIRIn
In THE sETTInG of HaaRT
Treatment of hepatitis C infection with pegylated in-
terferon and ribavirin may be better tolerated if start-
ed  without  concurrent  HaaRT  [28].  Therefore,  if
HIV infection is not advanced and there is no indica-
tion for HaaRT in the presence of high CD4-counts
(>500/ﾵl), a treatment of chronic hepatitis C infection
should be started prior to initiation of HaaRT [29].
In a recent analysis of one of the largest studies on
the  treatment  of  HIV-infected  with  HCV  infection,
the aPRICoT study, a relative CD4-cell count above
25 % was associated with better treatment outcome
than lower CD4-cell counts and initiation of HaaRT
is strongly recommended prior to HCV therapy if the
CD4-cell count is < 350/ﾵl [30]. anti-HCV therapy in
HIV  co-infected  individuals  has  been  shown  to  be
complicated  by  additive  drug  toxicities  of  pegylated
interferon and ribavirin with the antiretroviral nucleo-
sides  didanosine  [31,  32],  zidovudine  [33-35]  and
stavudine [36]. More recently, competitive phosphory-
lation  between  the  guanosine  nucleoside  analogues
abacavir and ribavirin has been hypothesized to fur-
ther compromise anti-HCV treatment efficacy [37-39],
though this effect was no longer observed in analysis
restricted to patients who had received weight based
doses of ribavirin [39, 40]. If feasible from the per-
spective of resistance and antiretroviral activity of the
aRT regimen, a tenofovir-based nucleoside backbone
or even nRTI-free HaaRT should be chosen for the
duration  of  anti-HCV  therapy.  In  countries  where
tenofovir is not yet licensed or contraindications for
the  use  of  tenofovir  exist,  an  abacavir  based  nRTI
backbone  may  be  considered  if  adequate  ribavirin
dosages are chosen. Therapeutic drug monitoring of
ribavirin would also be an alternative to ensure that
adequate  ribavirin  levels  of  >3.2  ﾵg/ml  are  being
achieved [39]. 
DIaGnosTIC PRoCEDuREs foR HCV 
In HIV Co-InfECTIon
Due to the increased prevalence of HCV co-infection
every  HIV-positive  patient  should  be  evaluated  for
anti-HCV antibodies at the time of first presentation
and on an annual basis thereafter (Table 1). It is im-
portant  to  remember  that  anti-HCV  seroconversion
after acute HCV infection may be significantly delayed
in HIV-positive patients and 5% of patients had not
developed anti-HCV antibodies despite ongoing viral
replication for one year in a recent study [41]. More-
over, anti-HCV antibodies may be lost during follow-
up, in particular with advanced degrees of immunode-
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raised liver transaminases testing for HCV-Rna may
be warranted in order to rule out occult or acute HCV-
infection. 
Before starting anti-HCV therapy determination of
HCV genotype and HCV viral load is necessary to es-
timate the odds for sVR and to determine the rough
grids for treatment duration. Current therapy is partic-
ularly recommended in patients with a high likelihood
of achieving sustained virological response (sVR), i.e.
genotypes 2 or 3 and patients infected with genotype 1
if the viral load is < 400 000 Iu/ml (Table 1). Recent-
ly,  first  data  suggested  that  the  level  of  HCV-Rna
may also influence the natural course of HCV infec-
tion in HIV-infected individuals [43]. In this analysis
of the EurosIDa cohort high HCV viral load above
800 000 Iu/ml was associated with an increased rate
of liver related death. as this is in contrast with all
data from HCV-monoinfection it should, however, be
discussed with caution. 
liver fibrosis staging may help to guide therapeutic
decisions  in  co-infected  patients.  However,  a  liver
biopsy is not mandatory for considering treatment of
chronic  HCV.  In  case  of  liver  biopsy  or  fibroscan
demonstrating lower stages of liver fibrosis (f0-1), re-
gardless of HCV genotype, treatment can be deferred.
In these cases, fibrosis assessment should be carried
out at frequent intervals to monitor for fibrosis pro-
gression.  serum  markers  for  liver  fibrosis  such  as
aPRI, fIB-4, fibrotest and others have been validated
in HIV/HCV co-infected patients and may help to as-
sess and monitor the extent of liver fibrosis. a liver
disease stage assessment is especially important to per-
form in patients with a low chance of sVR. Patients
who are diagnosed with liver cirrhosis must also be
evaluated  for  oesophageal  varices  and  hepatocellular
carcinoma and monitored accordingly thereafter.
More recently, insulin resistance, which can be de-
termined using the homeostasis model assessment of
insulin resistance [44], has been repeatedly reported as
a negative predictor of achievement of sVR [45, 46]
and may therefore also be considered during pretreat-
ment  evaluation.  Though  currently  there  is  no  data
suggesting that treatment of insulin resistance prior to
start of pegylated interferon and ribavirin therapy ac-
tually translates into higher rates of sVR, experts rec-
ommend to effectively manage insuline resistance be-
fore treating HCV infection if possible [29].
Determination of antinuclear (ana) and liver kid-
ney  microsome  (lKM)  autoantibodies  can  help  to
identify underlying autoimmune hepatitis [47], a dis-
ease which may significantly worsen under interferon
therapy. Therefore patients with a homogenous pat-
tern of ana or positive anti-lKM should be further
evaluated for autoimmune hepatitis, especially in the
presence of alT elevation during treatment. similarly
screening for thyroid autoantibodies will help to iden-
tify individuals at particular risk for the development
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Table 1. Diagnostic procedures for hepatitis C in HIV co-infection.
Diagnosis of hepatitis C
HCV-ab (positive 1-5 months after infection, may rarely be lost with immunosuppression)
HCV-Rna levelsa (in particular predicts response to treatment)
Status of liver damage
Grading of fibrosis (e. g. fibroscan, liver biopsy, serum fibrosis markersb)
Hepatic synthetic function (e. g. coagulation, albumin, CHE)
ultrasound and afP every 6 months in cirrhotics (gastroscopy upon diagnosis of cirrhosis and every 1-2 years thereafter)
Before HCV treatment
HCV genotype and serum HCV-Rna
autoantibodies (ana, lKM1)c
TsH, thyroid autoantibodies
Monitoring of HCV treatment
Differential blood count and liver enzymes every 2-4 weeks
HCV-Rna at week 4 (to evaluate rapid virological response),and weeks 12, 24, and 48 (72 if  applicable) and 24 weeks after
stopping HCV therapy
CD4-count every 12 weeks
TsH every 12 weeks
Recommendations according to the current EaCs guidelines on the treatment of HIV/HCV co-infection.
a) low viral load defined as less than 400,000 – 500,000 Iu/ml when using PegInf+RBV. There is no standard conversion for-
mula for converting the amount of HCV-Rna reported in copies/ml to the amount reported in Iu/ml. The conversion factor
ranges from about one to five HCV-Rna copies per Iu/ml.
b) serum fibrosis markers include aPRI, fIB-4, Hyaluronic acid, fibrometer, fibrotest, forns, Hepascore and other indices; re-
cently more complex tests such as fibrometer, fibrotest and Hepascore have shown to more accurately predict liver fibrosis
than simple biochemical tests such as aPRI, fIB-4 or forns.
c) Patients with positive anti lKM or ana with homogeneous pattern should be evaluated for concurrent autoimmune hepati-
tis especially in the presence of alT elevation during treatment.
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stimulating hormone (TsH) at baseline and every 12
weeks  under  therapy  helps  to  identify  patients  with
thyroid dysfunction under interferon therapy and al-
lows early therapeutic intervention.
During  interferon  and  ribavirin  therapy,  the  most
common adverse events observed are flu-like symp-
toms, anemia, leucopenia and mood disorders. flu-like
symptoms may be severe and can require concomitant
therapy  with  non-steroidal  anti-inflammatory  drugs
(nsaID).  starting  nsaID  a  few  hours  before  the
weekly injection of pegylated interferon and continue
for another 24 – 48 hours after the injection may help
to stop or relief symptoms in severely affected indi-
viduals. The maximum hemoglobin loss is usually ob-
served within the first 12 weeks of interferon and rib-
avirin therapy and frequent monitoring at 1 - 2 week
intervals is advised during this time in order to timely
adjust ribavirin doses accordingly (Table 1). Particular
attention must be given to patients with reduced crea-
tinine clearance who have a higher risk for ribavirin as-
sociated anemia. In case of creatinine clearance <50
ml/min ribavirin therapy should only be started with
reduced doses and after consultation with an experi-
enced hepatologist and/or nephrologist. Determina-
tion of week 2 hemoglobin concentrations may help
to estimate the full extent of ribavirin induced anemia
and allow dose modifications in patients at risk earlier
[51]. Patients with preexisting coronary heart disease
are more vulnerable to ribavirin associated anemia and
subsequently  lower  thresholds  of  hemoglobin  decay
must be taken into account when assessing the need
for ribavirin dose reductions. In patients with persist-
ing anemia despite ribavirin dose reductions interferon
induced auto-immune anemia should be a differential
diagnosis.  observed  leucopenia  and  thrombocytope-
nia are mainly due to the interferon associated bone
marrow suppression and may require dose adaptations
according to the summary of product characteristics
of the interferon used.  
Mood  disorders  are  frequently  encountered  in
HCV-positive  patients  undergoing  interferon  based
therapies. Patients with preexistent psychiatric comor-
bidities  should  be  evaluated  prior  and  ideally  moni-
tored  during  interferon  therapy  by  a  psychiatrist.  In
case mood disorders such as depression occur during
the  treatment  course,  pharmacologic  interventions
have shown to be of great success and few patients
have to stop interferon therapy due to psychiatric ad-
verse events [52].
THERaPy of HEPaTITIs C InfECTIon
Current treatment of choice is pegylated interferon in
combination with ribavirin. The standard dose for pe-
gylated interferon alfa-2a is 180 ﾵg once weekly, and
for pegylated interferon alfa-2b it is 1.5 ﾵg/kg body-
weight once weekly. In contrast to HCV monoinfected
patients  in  HIV/HCV  coinfected  patients  a  body-
weight-adapted  dosage  of  ribavirin  is  recommended
for all HCV genotypes because historical comparison
demonstrated superiority of a weight-adapted dosage
also in patients with genotype 2 or 3 infections [53].
Patients  with  a  bodyweight  <  75  kg  should  receive
1000 mg ribavirin, patients ≥ 75 kg 1200 mg per day. 
The duration of treatment should be individualized
according to HCV genotype, baseline HCV viral load,
and response to treatment (figure 1, [29]). Based on
the data from the PREsCo trial patients with geno-
type 1 and 4 infections should be treated for 48 weeks
in case of a rapid HCV-Rna clearance below the level
of detection at week 4 (rapid virological response). In
all other cases treatment should be prolonged to 72
weeks [54]. on the other side, in patients with a rapid
virological response, i.e. a negative HCV-Rna at week
4 and a genotype 2 or 3 infection, the overall treat-
ment course may be reduced to 24 weeks. However,
this should be only done in patients with a low base-
line HCV viral load < 400 000 I.u./ml and only mini-
mal liver fibrosis [55]. all other patients with a geno-
type 2 or 3 infection should be treated for 48 weeks.
Treatment may be stopped if insufficient virological
response  is  observed.  Thus,  if  the  decay  of  HCV-
Rna is less than 2 log10 at week 12 or HCV-Rna is
still positive at week 24 treatment should be stopped.
under these treatment modalities, the response rates
in  HIV/HCV  coinfected  patients  have  significantly
improved  over  the  years,  closing  the  gaps  between
HCV  monoinfected  and  HIV/HCV  coinfected  pa-
tients  (Table  2).  Currently  in  HIV/HCV  coinfected
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Fig. 1. Guidelines of the European
aIDs society (EaCs) for the treat-
ment of chronic hepatitis C infec-
tion in HIV/HCV coinfected indi-
viduals. 
W = week, neg = negative, pos =
positive, G = HCV-genotype
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Table 2. studies on the treatment of chronic HCV infection in HIV/HCV co-infected patients.
Study Number  Study type PegIFN Therapy Patient characteristics SVR rates
patients†
Duration RBV dosing High VL GT1 IDU Overall GT 1/4 GT 2/3
mg/day % % % % % %
laguno et al. 2004 52 prospective randomized  24 – 48 800 - 1200 47* 49 82 44 38 53
[61] controlled clinical trial
nunez et al. 2007  389 prospective clinical trial 24 - 72 1000 - 1200 67* 49 90 50 35 72
[62]
laguno et al. 2009  182 prospective randomized  48 800 - 1200 59* 45 76 44 30 66 
[63] controlled clinical trial
Torriani et al. 2004  289 prospective randomized  48 800 72* 61 62 40 29‡ 62
[64] controlled clinical trial
Mira et al. 2009  542 observational cohort study 24 - 48 600 – 1500 58* 54 85 38 25 63
[65]
Rodriguez-Torres  410 prospective randomized  48 800 - 1200 80* 100 n.r. - 21 -
et al. 2009 [66] controlled clinical trial
Voigt et al. 2005  122 prospective clinical trial 24 - 48 800 45* 56 61 25 18 44
[67]
Berenguer et al.  557 observational cohort study # # 61* 51 80 32 17 45
2009 [68]
Carrat et al. 2004  205 prospective randomized  48 800 63* 48 80 27 17 44$
[69] controlled clinical trial
Chung et al. 2004 66 prospective randomized  48 600 – 1000ﾧ 83* 77 not rep. 27 14‡ 73$
[70] controlled clinical trial
† number of patients who received pegylated interferon; 
* high viral load defined as: Chung et al. > 1 000 000 Iu/ml; Rodriguez-Torres et al. > 800 000 Iu/ml; Voigt et al., laguno et al. Torriani et al. > 800 000 Iu/ml; Mira et al., laguno et al.,
nunez et al. HCV-Rna > 600 000 Iu/ml; Berenguer et al., Carrat et al. > 500 000 Iu/ml; 
‡ only reported for GT1 infections; 
# reported as median 13.3 and 14.0 mg/kg body weight / day and median 8 and 11 months of treatment duration for the respective treatment group; $ Carrate et al. sVR rate reported for
GT 2,3 or 5 infections: Chung et al. sVR rate reported for non-1 genotypes; 
ﾧ dose escalating regimen, starting at 600 mg; n.r. rot reported in the abstract
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1patients a sustained virological response, i.e. a negative
HCV-Rna 24 weeks after stop of treatment, is ob-
served in genotype 1 or 4 infections in about 35 % and
in genotype 2 and 3 infections in about 70 % of pa-
tients [56]. 
In patients with acute HCV infection, HCV therapy
is recommended if HCV-Rna is confirmed positive
(1 week apart) by week 12 post HCV transmission, as
sVR rates following treatment of acute HCV-infection
are higher than for treatment of chronic HCV [57].
Most experts recommend therapy for 24 weeks with
Peg-Inf and ribavirin; however the duration of thera-
py and use of ribavirin is currently under discussion.
HCV-Rna levels at week 4 and 12 may help to guide
treatment duration [58]. 
non-REsPonDER
after failure of a modern pegylated interferon therapy
with weight based ribavirin dosage according to pre-
sent guidelines there is at present no reasonable treat-
ment  option  for  HIV/HCV  coinfected  patients.  an
interferon  maintenance  therapy  in  order  to  delay  or
stop  the  progression  of  liver  fibrosis  has  been  dis-
cussed  in  the  past  as  a  possible  treatment  option.
However, within the two largest studies on this issue
(HalT-C  for  HCV  monoinfected  and  slaM-C  for
HCV/HIV coinfected patients [59, 60]) this treatment
option did not result in any benefit for the patients so
that no continuation of interferon treatment is useful
after treatment failure.
Patients who have been treated in the past with a
standard interferon (not pegylated) or without / with-
out sufficient dosage of ribavirin should be individual-
ly discussed with an experienced hepatologist / HIV
specialist in how far a new treatment with pegylated
interferon in combination with ribavirin may be useful
and  may  result  in  sustained  virological  response.  at
present a whole array of new small molecules for the
treatment  of  hepatitis  C  is  in  clinical  development.
Many of the new drugs - like the most advanced in
clinical development telaprevir and boceprevir - are,
however, metabolized via the cytochrome P-450 sys-
tem so that relevant pharmacokinetic interactions with
antiretroviral  drugs,  in  particular  ritonavir  boosted
protease  inhibitors  and  non-nucleoside  reverse  tran-
scriptase  inhibitors,  are  to  be  expected.  In  addition
most  HCV-protease  inhibitors  do  not  seem  to  have
marked antiviral efficacy against HCV genotype 3 and
4 and are designed for highest efficacy in the difficult
to treat genotype 1 infection. Thus at present it is not
foreseeable when these new compounds will be avail-
able for HIV/HCV coinfected patients in clinical rou-
tine. 
ConClusIon
Due to the enhanced risk for progression of chronic
hepatitis  C,  every  HIV/HCV  coinfected  patient
should be evaluated for treatment with a pegylated in-
terferon ribavirin combination therapy. The standard
of care for the treatment of chronic HCV infection in
HIV-infected remains a pegylated interferon in combi-
nation with weight-adapted ribavirin. The duration of
therapy  is  dependent  on  HCV  genotype,  baseline
HCV viral load, and treatment response. In the last
years,  due  to  the  introduction  of  weight  based  rib-
avirin  and  an  overall  prolongation  of  the  course  of
treatment  treatment  response  rates  in  HIV/HCV
coinfected patients have been enhanced and are com-
ing closer to response rates observed in HCV monoin-
fected patients. Currently  treatment response rates in
patients with genotype 1 and 4 infections and  2 and 3
infections are observed in 35% and  70 % of patients
respectively.
Higher CD4-cell counts are associated with higher
treatment response rates. Thus HaaRT should not be
withheld from patients due to concerns of drug relat-
ed hepatotoxicity and in patients with reduced CD4-
cell  counts  HaaRT  should  be  started  first.  under
concomitant use of HaaRT and pegylated interferon
and ribavirin combination therapy drug to drug inter-
actions  and  cumulated  toxicity  between  nucleoside
analogues and anti-HCV therapy may be observed and
HaaRT should be adjusted accordingly. Importantly
concomitant didanosine use is contraindicated and zi-
dovudine and stavudine should be avoided if possible.
The development of new drugs for the treatment
of chronic hepatitis C represents a promising perspec-
tive also for HIV positive patients. However, due to
necessary  pharmacokinetic  interaction  studies,  these
substances will probably reach clinical routine for HIV
patients later than HCV monoinfected patients. There-
fore at present waiting for new substances is not an al-
ternative  to  a  modern  pegylated  interferon/ribavirin
therapy.
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